@misc{PolzinRassafBoehmetal.2013,
  author    = {Polzin, Amin and Rassaf, Tienush and Boehm, Andreas and Lueth, Anja and Kleuser, Burkhard and Zeus, Tobias and Kelm, Malte and Kroemer, Heyo K. and Schroer, Karsten and Rauch, Bernhard H.},
  title     = {Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction},
  series = {INTERNATIONAL JOURNAL OF CARDIOLOGY},
  volume    = {170},
  journal   = {INTERNATIONAL JOURNAL OF CARDIOLOGY},
  number    = {2},
  publisher = {ELSEVIER IRELAND LTD},
  address   = {CLARE},
  issn      = {0167-5273},
  doi       = {10.1016/j.ijcard.2013.10.050},
  pages     = {E23 -- E24},
  year      = {2013},
  language  = {en}
}
@inproceedings{BoehmPolzinLuethetal.2012,
  author    = {Boehm, Andreas and Polzin, A. and Lueth, Anja and Kleuser, Burkhard and Rassaf, T. and Kelm, M. and Kroemer, H. K. and Schroer, K. and Rauch, B. H.},
  title     = {The release of sphingosine-1-phosphate from human platelets during acute coronary syndrome is attenuated by aspirin},
  series = {NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY},
  volume    = {385},
  booktitle = {NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY},
  publisher = {Springer},
  address   = {New York},
  issn      = {0028-1298},
  pages     = {12 -- 12},
  year      = {2012},
  language  = {en}
}
@article{KellerCatalaLehnenHuebneretal.2014,
  author    = {Keller, Johannes and Catala-Lehnen, Philip and Huebner, Antje K. and Jeschke, Anke and Heckt, Timo and Lueth, Anja and Krause, Matthias and Koehne, Till and Albers, Joachim and Schulze, Jochen and Schilling, Sarah and Haberland, Michael and Denninger, Hannah and Neven, Mona and Hermans-Borgmeyer, Irm and Streichert, Thomas and Breer, Stefan and Barvencik, Florian and Levkau, Bodo and Rathkolb, Birgit and Wolf, Eckhard and Calzada-Wack, Julia and Neff, Frauke and Gailus-Durner, Valerie and Fuchs, Helmut and de Angelis, Martin Hrabe and Klutmann, Susanne and Tsourdi, Elena and Hofbauer, Lorenz C. and Kleuser, Burkhard and Chun, Jerold and Schinke, Thorsten and Amling, Michael},
  title     = {Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts},
  series = {Nature Communications},
  volume    = {5},
  journal   = {Nature Communications},
  publisher = {Nature Publ. Group},
  address   = {London},
  issn      = {2041-1723},
  doi       = {10.1038/ncomms6215},
  pages     = {13},
  year      = {2014},
  abstract  = {The hormone calcitonin (CT) is primarily known for its pharmacologic action as an inhibitor of bone resorption, yet CT-deficient mice display increased bone formation. These findings raised the question about the underlying cellular and molecular mechanism of CT action. Here we show that either ubiquitous or osteoclast-specific inactivation of the murine CT receptor (CTR) causes increased bone formation. CT negatively regulates the osteoclast expression of Spns2 gene, which encodes a transporter for the signalling lipid sphingosine 1-phosphate (S1P). CTR-deficient mice show increased S1P levels, and their skeletal phenotype is normalized by deletion of the S1P receptor S1P(3). Finally, pharmacologic treatment with the nonselective S1P receptor agonist FTY720 causes increased bone formation in wild-type, but not in S1P(3)-deficient mice. This study redefines the role of CT in skeletal biology, confirms that S1P acts as an osteoanabolic molecule in vivo and provides evidence for a pharmacologically exploitable crosstalk between osteoclasts and osteoblasts.},
  language  = {en}
}
@article{BarceloCoblijnLauraMartindeAlmeidaetal.2011,
  author    = {Barcelo-Coblijn, Gwendolyn and Laura Martin, Maria and de Almeida, Rodrigo F. M. and Antonia Noguera-Salva, Maria and Marcilla-Etxenike, Amaia and Guardiola-Serrano, Francisca and Lueth, Anja and Kleuser, Burkhard and Halver, John E. and Escriba, Pablo V.},
  title     = {Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy},
  series = {Proceedings of the National Academy of Sciences of the United States of America},
  volume    = {108},
  journal   = {Proceedings of the National Academy of Sciences of the United States of America},
  number    = {49},
  publisher = {National Acad. of Sciences},
  address   = {Washington},
  issn      = {0027-8424},
  doi       = {10.1073/pnas.1115484108},
  pages     = {19569 -- 19574},
  year      = {2011},
  abstract  = {The mechanism of action of 2-hydroxyoleic acid (2OHOA), a potent antitumor compound, has not yet been fully elucidated. Here, we show that human cancer cells have markedly lower levels of sphingomyelin (SM) than nontumor (MRC-5) cells. In this context, 2OHOA treatment strongly augments SM mass (4.6-fold), restoring the levels found in MRC-5 cells, while a loss of phosphatidylethanolamine and phosphatidylcholine is observed (57 and 30\%, respectively). The increased SM mass was due to a rapid and highly specific activation of SM synthases (SMS). This effect appeared to be specific against cancer cells as it did not affect nontumor MRC-5 cells. Therefore, low SM levels are associated with the tumorigenic transformation that produces cancer cells. SM accumulation occurred at the plasma membrane and caused an increase in membrane global order and lipid raft packing in model membranes. These modifications would account for the observed alteration by 2OHOA in the localization of proteins involved in cell apoptosis (Fas receptor) or differentiation (Ras). Importantly, SMS inhibition by D609 diminished 2OHOA effect on cell cycle. Therefore, we propose that the regulation of SMS activity in tumor cells is a critical upstream event in 2OHOA antitumor mechanism, which also explains its specificity for cancer cells, its potency, and the lack of undesired side effects. Finally, the specific activation of SMS explains the ability of this compound to trigger cell cycle arrest, cell differentiation, and autophagy or apoptosis in cancer cells.},
  language  = {en}
}